Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 3:499-501 (2006)
© 2006 The American Thoracic Society
doi: 10.1513/pats.200603-069MS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lomas, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lomas, D. A.

Parker B. Francis Lectureship. Antitrypsin Deficiency, the Serpinopathies, and Chronic Obstructive Pulmonary Disease

David A. Lomas

Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom

Correspondence and requests for reprints should be addressed to Prof. David Lomas, Sc.D., F.R.C.P., Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 2XY, UK. E-mail: dal16{at}cam.ac.uk

ABSTRACT

{alpha}1-Antitrypsin deficiency is the only genetic factor that is widely recognized to predispose smokers to chronic obstructive pulmonary disease. We have shown that the plasma deficiency results from point mutations perturbing the structure of the protein to favor sequential linkage between the reactive center loop of one molecule and ß-sheet A of another. These polymers are retained within the liver to form the periodic acid-Schiff–positive inclusions that are characteristic of the disease. Intracellular polymerization also explains the retention of mutants of other members of the serine proteinase inhibitor (or serpin) superfamily to cause diseases as diverse as thrombosis, angio-edema, and dementia. In view of the common mechanism, we have grouped these conditions together as the serpinopathies. Intrapulmonary Z {alpha}1-antitrypsin similarly forms polymers within the alveolar space. These polymers are inactive as a proteinase inhibitor and act as a chemoattractant for neutrophils. This conformational transition may explain the excessive inflammation that underlies the progressive emphysema associated with Z {alpha}1-antitrypsin deficiency.

Key Words: cirrhosis • emphysema • polymerization • polymers • serpin

{alpha}1-ANTITRYPSIN DEFICIENCY RESULTS FROM THE POLYMERIZATION OF MUTANT {alpha}1-ANTITRYPSIN WITHIN HEPATOCYTES

{alpha}1-Antitrypsin is an acute phase glycoprotein that is synthesized and secreted by the liver. It bathes all the tissues of the body, with its primary role being to inhibit the enzyme neutrophil elastase. The most important deficiency mutation of {alpha}1-antitrypsin is the Z allele (Glu342Lys). Approximately 4% of northern Europeans are heterozygous for the Z allele (PI*MZ), with approximately 1 in 2,000 being homozygotes (PI*Z). The Z allele results in the retention of synthesized {alpha}1-antitrypsin within the endoplasmic reticulum of hepatocytes. The accumulation of abnormal protein starts in utero and is characterized by diastase-resistant, periodic acid-Schiff (PAS)–positive inclusions of {alpha}1-antitrypsin within the periportal cells. This intrahepatic accumulation of Z {alpha}1-antitrypsin predisposes the homozygote to neonatal hepatitis, juvenile cirrhosis, and hepatocellular carcinoma. The lack of circulating plasma {alpha}1-antitrypsin leaves the lungs exposed to enzymatic damage that is believed to underlie the adult-onset emphysema.

We have shown that the Z variant of {alpha}1-antitrypsin is retained within hepatocytes as it causes a unique conformational transition and protein–protein interaction (1). The mutation distorts the relationship between the reactive center loop and ß-sheet A (Figure 1A). The consequent perturbation in structure allows the formation an unstable intermediate (M*) and the formation of polymers in which the reactive center loop of one {alpha}1-antitrypsin molecule sequentially inserts into ß-sheet A of another (1–6). Spectroscopic analysis has demonstrated that oligomers of {alpha}1-antitrypsin form during an initial lag phase and that these then condense to form a heterogenous mixture of longer polymers (2, 7). It is these polymers (Figure 1B) that accumulate within the endoplasmic reticulum of hepatocytes to form the PAS-positive inclusions that are the hallmark of Z {alpha}1-antitrypsin liver disease (1, 6, 8). The process of intrahepatic polymerization also underlies the severe plasma deficiency of the Siiyama (Ser53Phe) and Mmalton (deletion of phenylalanine at position 52) alleles that are the commonest cause of {alpha}1-antitrypsin deficiency in Japan and Sardinia, respectively. Moreover, this process explains the mild plasma deficiency of the common S (Glu264Val) and rare I (Arg39Cys) alleles of {alpha}1-antitrypsin (see References 9 and 10 for reviews). In each case, there is strong genotype–phenotype correlation that can be explained by the molecular instability caused by the mutation and, in particular, the rate at which the mutant forms polymers. Those mutants that cause the most rapid polymerization cause the most retention of {alpha}1-antitrypsin within the liver. This, in turn, correlates with the greatest risk of liver damage and cirrhosis, and the most severe plasma deficiency.


Figure 1
Figure 1
View larger version (160K):
[in this window]
[in a new window]
  		Figure 1. Mutant Z {alpha}1-antitrypsin is retained within hepatocytes as polymers. (A) The structure of {alpha}1-antitrypsin is centered on ß-sheet A (green) and the mobile reactive center loop (red). Polymer formation results from the Z variant of {alpha}1-antitrypsin (Glu342Lys at P17; arrowed) or mutations in the shutter domain (blue circle) that open ß-sheet A to favor partial loop insertion and the formation of an unstable intermediate (M*). The patent ß-sheet A can then accept the loop of another molecule to form a dimer (D), which then extends into polymers (P). The individual molecules of {alpha}1-antitrypsin within the polymer are colored red, yellow, and blue. Support for this came from the finding of polymers within hepatocytes and in plasma of individuals with {alpha}1-antitrypsin deficiency (1, 6, 14). (B) The polymers have a "beads on a string appearance" on electron microscopy (Figure 1A modified by permission from Reference 5 and Figure 1B reproduced by permission from Reference 14).

 
THE SERPINOPATHIES

The phenomenon of loop-sheet polymerization is not restricted to {alpha}1-antitrypsin and has now been reported in mutants of other members of the serpin superfamily to cause disease. Naturally occurring mutations have been described in the shutter (Figure 1A) and other domains of the plasma proteins C1-inhibitor, antithrombin, and {alpha}1-antichymotrypsin. These mutations destabilize the serpin architecture to allow the formation of inactive reactive loop–ß-sheet polymers that are also retained within hepatocytes. The associated plasma deficiency results in uncontrolled activation of proteolytic cascades and angio-edema, thrombosis, and chronic obstructive pulmonary disease, respectively (see References 9 and 10 for reviews). More recently, a mutation in heparin cofactor II (Glu428Lys) has been associated with plasma deficiency, but as yet this has not been shown to cause disease (11). The mutation is of particular interest as it is the same as the Z allele that causes polymerization and deficiency of {alpha}1-antitrypsin. We have shown that this same mutation also causes temperature-dependent polymerization and inactivation of the Drosophila serpin necrotic (12).

Perhaps the most striking finding of polymer-associated disease is the inclusion body dementia of familial encephalopathy with neuroserpin inclusion bodies (FENIB) (13). This is an autosomal dominant dementia characterized by eosinophilic neuronal inclusions of neuroserpin (Collins' bodies) in the deeper layers of the cerebral cortex and the substantia nigra. The inclusions are PAS positive and diastase resistant and bear a striking resemblance to those of Z {alpha}1-antitrypsin that form within the liver. The observation that FENIB was associated with a mutation (Ser49Pro) in the neuroserpin gene that was homologous to one in {alpha}1-antitrypsin that causes cirrhosis (Ser53Phe) (14) strongly indicated a common molecular mechanism. This was confirmed by the finding that the neuronal inclusion bodies of FENIB were formed by entangled polymers of neuroserpin with identical morphology to those isolated from hepatocytes from an individual with Z {alpha}1-antitrypsin–related cirrhosis (13). Five families with four different point mutations have now been identified with FENIB (15). These have allowed comparison of the severity of the mutation (as predicted by molecular modeling), the number of inclusions, and the age of onset of dementia. Once again, there is a striking genotype–phenotype correlation that can be explained by the rate at which the mutants form intracellular polymers (Table 1). The more rapid the rate of polymerization, the more the protein is retained as intraneuronal inclusions and the earlier the onset of the clinical phenotype (see Reference 16 for review).


View this table:
[in this window]
[in a new window]
  		TABLE 1. CORRELATION BETWEEN THE RATE OF POLYMERIZATION OF MUTANTS OF NEUROSERPIN, THE NUMBER OF INCLUSIONS, AND THE SEVERITY OF THE ASSOCIATED DEMENTIA

 
In view of the common mechanism (serpin polymerization) that underlies all these conditions, we have grouped them together as the serpinopathies (9, 10). We and others have shown that, at least in vitro, serpin polymerization can be attenuated by competing reactive loop peptides, chemical chaperones, and manipulating an exposed surface cavity (see Reference 17 for review). These approaches now need to be converted into effective drugs if we are to develop novel therapies for the serpinopathies.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Emphysema associated with plasma deficiency of {alpha}1-antitrypsin is widely believed to be due to the reduction in plasma levels of {alpha}1-antitrypsin to 10 to 15% of normal. This makes the lungs vulnerable to uncontrolled digestion by neutrophil elastase. The situation is exacerbated because the Z mutation reduces the association rate between {alpha}1-antitrypsin and neutrophil elastase by approximately fivefold, so the {alpha}1-antitrypsin available within the lung is not as effective as the normal M protein (18, 19). {alpha}1-Antitrypsin is present within the lung by passive diffusion or local secretion by bronchial epithelial cells and macrophages. In each case, the secreted protein contains the Z (or other) mutation and hence the propensity to spontaneously form polymers. We have detected polymers within lung lavage (20) and explanted tissue (21) from patients with emphysema associated with Z {alpha}1-antitrypsin deficiency but not in samples from individuals with emphysema and normal {alpha}1-antitrypsin phenotypes. This conformational transition inactivates {alpha}1-antitrypsin as a proteinase inhibitor, thereby further reducing the already depleted levels of {alpha}1-antitrypsin that are available to protect the alveoli (see Reference 9 for review). Moreover, the conversion of {alpha}1-antitrypsin from a monomer to a polymer changes it to a chemoattractant for human neutrophils (22, 23). The magnitude of the effect is similar to that of the chemoattractant C5a and is present over a range of physiologic concentrations (EC50, 4.5 ± 2 µg/ml). These chemoattractant properties of polymers may explain the excess number of neutrophils in bronchoalveolar lavage (24) and in tissue sections of lung parenchyma (21) from individuals with Z {alpha}1-antitrypsin deficiency. Moreover, polymers may contribute to the excess inflammation that is apparent even in individuals with Z {alpha}1-antitrypsin deficiency with very early lung disease (25) and may drive the progressive inflammation that continues even after cessation of smoking. The inflammatory properties of polymers may also explain other inflammatory conditions that have been associated with Z {alpha}1-antitrypsin deficiency: panniculitis (26), pancreatitis (27), Wegener's granulomatosis (28), glomerulonephritis, and asthma (29).

ACKNOWLEDGMENTS

The author thanks all past and present members of the laboratory for their many years of hard work.

FOOTNOTES

Supported by the Medical Research Council (United Kingdom), the Wellcome Trust, and Papworth NHS Trust.

Conflict of Interest Statement: D.A.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

(Received in original form March 17, 2006; accepted in final form April 21, 2006)

REFERENCES

  1. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z {alpha}1-antitrypsin accumulation in the liver. Nature 1992;357:605–607.[CrossRef][Medline]
  2. Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA. A kinetic mechanism for the polymerisation of {alpha}1-antitrypsin. J Biol Chem 1999;274:9548–9555.[Abstract/Free Full Text]
  3. Sivasothy P, Dafforn TR, Gettins PGW, Lomas DA. Pathogenic {alpha}1-antitrypsin polymers are formed by reactive loop-ß-sheet A linkage. J Biol Chem 2000;275:33663–33668.[Abstract/Free Full Text]
  4. Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. Six-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerisation: implications for the prevention of Z {alpha}1-antitrypsin related cirrhosis. J Biol Chem 2002;277:6771–6774.[Abstract/Free Full Text]
  5. Gooptu B, Hazes B, Chang W-SW, Dafforn TR, Carrell RW, Read RJ, Lomas DA. Inactive conformation of the serpin {alpha}1-antichymotrypsin indicates two stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 2000;97:67–72.[Abstract/Free Full Text]
  6. Janciauskiene S, Eriksson S, Callea F, Mallya M, Zhou A, Seyama K, Hata S, Lomas DA. Differential detection of PAS-positive inclusions formed by the Z, Siiyama and Mmalton variants of {alpha}1-antitrypsin. Hepatology 2004;40:1203–1210.[CrossRef][Medline]
  7. Purkayastha P, Klemke JW, Lavender S, Pyola R, Cooperman B, Gai F. {alpha}1-Antitrypsin polymerisation: a fluorescence correlation spectroscopic study. Biochemistry 2005;44:2642–2649.[CrossRef][Medline]
  8. An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of alpha-l-antitrypsin mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology 2005;41:160–167.[CrossRef][Medline]
  9. Lomas DA, Mahadeva R. Alpha-1-antitrypsin polymerisation and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 2002;110:1585–1590.[CrossRef][Medline]
  10. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 2002;346:45–53.[Free Full Text]
  11. Corral J, Aznar J, Gonzalez-Conejero R, Villa P, Minano A, Vaya A, Carrell RW, Huntington JA, Vicente V. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation 2004;110:1303–1307.[Abstract/Free Full Text]
  12. Green C, Brown G, Dafforn TR, Reichhart JM, Morley T, Lomas DA, Gubb D. Drosophila necrotic mutations mirror disease-associated variants of human serpins. Development 2003;130:1473–1478.[Abstract/Free Full Text]
  13. Davis RL, Shrimpton AE, Holohan PD, Bradshaw C, Feiglin D, Collins GH, Sonderegger P, Kinter J, Becker LM, Lacbawan F, et al. Familial dementia caused by polymerisation of mutant neuroserpin. Nature 1999;401:376–379.[Medline]
  14. Lomas DA, Finch JT, Seyama K, Nukiwa T, Carrell RW. {alpha}1-Antitrypsin Siiyama (Ser53->Phe): further evidence for intracellular loop-sheet polymerisation. J Biol Chem 1993;268:15333–15335.[Abstract/Free Full Text]
  15. Davis RL, Shrimpton AE, Carrell RW, Lomas DA, Gerhard L, Baumann B, Lawrence DA, Yepes M, Kim TS, Piccardo P, et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002;359:2242–2247.[CrossRef][Medline]
  16. Lomas DA, Belorgey D, Mallya M, Miranda E, Kinghorn KJ, Sharp LK, Phillips RL, Page R, Robertson AS, Crowther DC. Molecular mousetraps and the serpinopathies. Biochem Soc Trans 2005;33:321–330.[CrossRef][Medline]
  17. Lomas DA, Belorgey D, Mallya M, Onda M, Kinghorn KJ, Sharp LK, Phillips RL, Page R, Crowther DC, Miranda E. Polymerisation underlies alpha-1-antitrypsin deficiency, dementia and other serpinopathies. Front Biosci 2004;9:2873–2891.[Medline]
  18. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type {alpha}1-antitrypsin is less competent than M1-type {alpha}1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;80:1366–1374.[Medline]
  19. Lomas DA, Evans DL, Stone SR, Chang WS, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of {alpha}1-antitrypsin. Biochemistry 1993;32:500–508.[CrossRef][Medline]
  20. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z {alpha}1-antitrypsin related emphysema. Am J Respir Cell Mol Biol 1998;18:670–674.[Abstract/Free Full Text]
  21. Mahadeva R, Atkinson C, Li Z, Stewart S, Janciauskiene S, Kelley DG, Parmar J, Pitman R, Shapiro SD, Lomas DA. Polymers of Z {alpha}1-antitrypsin co-localise with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005;166:377–386.[Abstract/Free Full Text]
  22. Parmar JS, Mahadeva R, Reed BJ, Farahi N, Cadwallader KA, Keogan MR, Bilton D, Chilvers ER, Lomas DA. Polymers of {alpha}1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002;26:723–730.[Abstract/Free Full Text]
  23. Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, McElvaney NGZ. {alpha}1-Antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004;125:1952–1957.[CrossRef][Medline]
  24. Morrison HM, Kramps JA, Burnett D, Stockley RA. Lung lavage fluid from patients with {alpha}1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci (Lond) 1987;72:373–381.[Medline]
  25. Rouhani F, Paone G, Smith NK, Krein P, Barnes P, Brantly ML. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with {alpha}1-antitrypsin deficiency. Chest 2000;117:250S–251S.[Medline]
  26. O'Riordan K, Blei A, Rao MS, Abecassis M. {alpha}1-Antitrypsin deficiency-associated panniculitis: resolution with intravenous {alpha}1-antitrypsin administration and liver transplantation. Transplantation 1997;63:480–482.[Medline]
  27. Seersholm N, Kok-Jensen A. Extrapulmonary manifestations of {alpha}1-antitrypsin deficiency [abstract]. Am J Respir Crit Care Med 2001;163:A343.
  28. Elzouki A-NY, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994;236:543–548.[Medline]
  29. Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH, Turino GM. Atopy, asthma, and emphysema in patients with severe {alpha}1-antitrypsin deficiency. Am J Respir Crit Care Med 1997;156:68–74.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lomas, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lomas, D. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS